Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer

Published:2017-05-24 Issue:5 Volume:25 Page:673-679
ISSN:0965-0407
Container-title:Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
language:en
Short-container-title:oncol res

Author:

Ma Cheng-Jen¹,Huang Ching-Wen¹,Yeh Yung-Sung¹,Tsai Hsiang-Lin¹,Hu Huang-Ming²,Wu I-Chen²,Cheng Tian-Lu³,Wang Jaw-Yuan¹

Affiliation:

1. Division of Gastroenterology and General Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

2. Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

3. Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan

Publisher

Cognizant, LLC

Subject

Cancer Research,Oncology,General Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy;Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics;2022-05-04

2. Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study;Frontiers in Oncology;2022-03-30

3. UGT1A1 Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review;Frontiers in Oncology;2022-03-09

4. Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting;Translational Oncology;2019-03

5. Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer;Cancer;2018-06-15